ArticleMolecular therapy. Methods & clinical development2021

Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity.

James M Termini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.